Lexicon Pharmaceuticals Inc. (LXRX) Financial Statements (2025 and earlier)

Company Profile

Business Address 2445 TECHNOLOGY FOREST BLVD.
THE WOODLANDS, TX 77381
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments237,957170,026138,35786,743152,275271,659
Cash and cash equivalent66,65622,46546,34564,065126,26336,112
Short-term investments171,301147,56192,01222,67826,012235,547
Receivables3,4731,010281439556,532
Inventory, net of allowances, customer advances and progress billings231381   4,243
Inventory231381   4,243
Other current assets4,5325,1302,4812,1645,0495,320
Total current assets:246,193176,547140,86688,921157,719337,754
Noncurrent Assets
Operating lease, right-of-use asset4,8325,524    
Property, plant and equipment2,4841,9872,0711,17629514,047
Intangible assets, net (including goodwill)44,54344,54344,54344,54344,54364,259
Goodwill44,54344,54344,54344,54344,54344,543
Intangible assets, net (excluding goodwill)      19,716
Other noncurrent assets3688286,8192,2691,2311,655
Other undisclosed noncurrent assets      
Total noncurrent assets:52,22752,88253,43347,98846,06979,961
TOTAL ASSETS:298,420229,429194,299136,909203,788417,715
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities45,24831,54623,17222,12435,16054,329
Accounts payable14,80114,38910,3959,1525,46912,178
Accrued liabilities30,44717,15712,77712,97229,69142,151
Deferred revenue      
Debt     11,64611,012
Total current liabilities:45,24831,54623,17222,12446,80665,341
Noncurrent Liabilities
Long-term debt and lease obligation, including:100,29899,5085,424  1,102
Long-term debt, excluding current maturities100,29899,508   234,171
Other undisclosed long-term debt and lease obligation   5,424  (233,069)
Liabilities, other than long-term debt6,9245,2655,4241,1906111,102
Other liabilities6,924 5,4241,1906111,102
Operating lease, liability  5,265    
Other undisclosed noncurrent liabilities   43,155  233,069
Total noncurrent liabilities:107,222104,77354,0031,190611235,273
Total liabilities:152,470136,31977,17523,31447,417300,614
Equity
Equity, attributable to parent145,95093,110117,124113,595156,371117,101
Common stock363245189150142106
Treasury stock, value(4,615)(2,885)(2,061)(7,518)(4,843)(3,817)
Additional paid in capital2,117,3251,862,5581,709,1441,608,7491,561,0961,462,172
Accumulated other comprehensive income (loss)11931(428)(10)(6)84
Accumulated deficit(1,967,242)(1,766,839)(1,589,720)(1,487,776)(1,400,018)(1,341,444)
Total equity:145,95093,110117,124113,595156,371117,101
TOTAL LIABILITIES AND EQUITY:298,420229,429194,299136,909203,788417,715

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues31,0811,20413929823,995322,073
Cost of revenue
(Cost of Product and Service Sold)
(616)(85)  (1,929)(3,231)
Gross profit:30,4651,11913929822,066318,842
Operating expenses(227,582)(172,869)(100,899)(87,388)(204,380)(180,628)
Other undisclosed operating income     134,5143,231
Operating income (loss):(197,117)(171,750)(100,760)(87,090)(47,800)141,445
Nonoperating income
(Other Nonoperating income)
12,2937,7321,5961342,7673,350
Interest and debt expense   (2,780)(802)(13,541)(20,676)
Income (loss) from continuing operations before income taxes:(184,824)(164,018)(101,944)(87,758)(58,574)124,119
Income tax benefit     2695,569
Income (loss) from continuing operations:(184,824)(164,018)(101,944)(87,758)(58,305)129,688
Income (loss) before gain (loss) on sale of properties:(87,758)(70,505)129,688
Loss from discontinued operations     (12,200) 
Other undisclosed net income     11,931445
Net income (loss):(184,824)(164,018)(101,944)(87,758)(58,574)130,133
Other undisclosed net loss attributable to parent(15,579)(13,101)    
Net income (loss) available to common stockholders, basic:(200,403)(177,119)(101,944)(87,758)(58,574)130,133
Dilutive securities, effect on basic earnings per share    (87,758)(58,574)135,200
Net income (loss) available to common stockholders, diluted:(200,403)(177,119)(101,944)(175,516)(117,148)265,333

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(184,824)(164,018)(101,944)(87,758)(58,574)130,133
Comprehensive income (loss):(184,824)(164,018)(101,944)(87,758)(58,574)130,133
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(15,491)(12,642)(418)(4)(90)96
Comprehensive income (loss), net of tax, attributable to parent:(200,315)(176,660)(102,362)(87,762)(58,664)130,229

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: